ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model

There is an urgent need for antivirals targeting the SARS-CoV-2 virus to fight the current COVID-19 pandemic. The SARS-CoV-2 main protease (3CLpro) represents a promising target for antiviral therapy. The lack of selectivity for some of the reported 3CLpro inhibitors, specifically versus cathepsin L...

Descripción completa

Detalles Bibliográficos
Autores principales: Vandyck, Koen, Abdelnabi, Rana, Gupta, Kusum, Jochmans, Dirk, Jekle, Andreas, Deval, Jerome, Misner, Dinah, Bardiot, Dorothée, Foo, Caroline S., Liu, Cheng, Ren, Suping, Beigelman, Leonid, Blatt, Lawrence M., Boland, Sandro, Vangeel, Laura, Dejonghe, Steven, Chaltin, Patrick, Marchand, Arnaud, Serebryany, Vladimir, Stoycheva, Antitsa, Chanda, Sushmita, Symons, Julian A., Raboisson, Pierre, Neyts, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997389/
https://www.ncbi.nlm.nih.gov/pubmed/33813272
http://dx.doi.org/10.1016/j.bbrc.2021.03.096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997389/
https://www.ncbi.nlm.nih.gov/pubmed/33813272
http://dx.doi.org/10.1016/j.bbrc.2021.03.096

Ejemplares similares